- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-4889
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
CDK4 inhibition diminishes p53 activation by MDM2 antagonists ; volume:9 ; number:9 ; day:11 ; month:9 ; year:2018 ; pages:1-16 ; date:9.2018
Cell death & disease ; 9, Heft 9 (11.9.2018), 1-16, 9.2018
- Urheber
-
Sriraman, Anusha
- Beteiligte Personen und Organisationen
-
Dickmanns, Antje
Najafova, Zeynab
Johnsen, Steven A.
Dobbelstein, Matthias
SpringerLink (Online service)
- DOI
-
10.1038/s41419-018-0968-0
- URN
-
urn:nbn:de:101:1-2018102814500845316868
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Sriraman, Anusha
- Dickmanns, Antje
- Najafova, Zeynab
- Johnsen, Steven A.
- Dobbelstein, Matthias
- SpringerLink (Online service)
Ähnliche Objekte (12)
Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
NMR high resolution spectroscopy and X-ray crystallography for development of MDM2/X-p53 interaction antagonists
Evolution of the p53-MDM2 pathway
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Small-Molecule Inhibitors of p53-MDM2 interactions
Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
Engineering a synthetic p53-Mdm2 network in budding yeast
Explaining oscillations and variability in the p53-Mdm2 system
Mad1 destabilizes p53 by preventing PML from sequestering MDM2
Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
NMR high resolution spectroscopy and X-ray crystallography for development of MDM2/X-p53 interaction antagonists
Evolution of the p53-MDM2 pathway
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Small-Molecule Inhibitors of p53-MDM2 interactions
Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
Engineering a synthetic p53-Mdm2 network in budding yeast
Explaining oscillations and variability in the p53-Mdm2 system
Mad1 destabilizes p53 by preventing PML from sequestering MDM2
Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
NMR high resolution spectroscopy and X-ray crystallography for development of MDM2/X-p53 interaction antagonists
Evolution of the p53-MDM2 pathway
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Small-Molecule Inhibitors of p53-MDM2 interactions
Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
Engineering a synthetic p53-Mdm2 network in budding yeast
Explaining oscillations and variability in the p53-Mdm2 system